Lobeline hydrochlorideLobeline hydrochloride
MedChemExpress (MCE)
HY-B0979
134-63-4
α-Lobeline hydrochloride
L-Lobeline hydrochloride
99.98%
4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months
-20°C, 1 month (sealed storage, away from moisture and light)
Room temperature in continental US
may vary elsewhere.
Lobeline (α-Lobeline) hydrochloride is a brain-penetrant nicotinic receptor agonist. Lobeline hydrochloride increases dopamine (DA) release by inhibiting DA uptake into synaptic vesicles, and altering presynaptic DA storage. Lobeline hydrochloride is effective in smoking cessation.
Lobeline (0.1-100 μM) hydrochloride evokes [3H]DA overflow calcium-independently[1]. Lobeline hydrochloride inhibits [3H]DA uptake into synaptosomes (IC50=80 μM) and vesicles (IC50=0.88 μM)[1].
Lobeline (0.3-3.0 mg/kg
s.c.
single dose) hydrochloride decreases d-methamphetamine self-administration in rats model[3]. Lobeline (3 mg/kg
s.c.
7 times during 7 sessions) hydrochloride specifically decreases responding for d-Methamphetamine in a noncompetitive manner, and increases tolerance development[3].
| | | |
| | | | | |
[1]. Teng L, et al. Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. J Pharmacol Exp Ther. 1997 Mar
280(3):1432-44. [Content Brief]
[2]. Monzurul Amin Roni, et al. Lobeline attenuates ethanol abstinence-induced depression-like behavior in mice. Alcohol. 2017 Jun:61:63-70. [Content Brief]
[3]. Harrod SB, et al. Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther. 2001 Jul
298(1):172-9. [Content Brief]